ArticleFrontiers in public health2025
Comprehensive evaluation of the development of traditional Chinese medicine industry in Shaanxi province based on PMC index model.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Computationally optimized molecularly imprinted electrochemical sensor based on biomass-derived biochar for paclobutrazol analysis in Radix Angelicae Sinensis.RSC advances · 2026Article
- Quantitative evaluation of China's smart aging healthcare policy under the background of silver economy development: based on PMC model.Frontiers in public health · 2026Article
- How to evaluate long-term care insurance policy based on policy tools and PMC index model: evidence from pilot cities in China.Frontiers in public health · 2025Article
- Quantitative evaluation and optimization of AI policy and regulatory texts for smart healthcare.Frontiers in public health · 2025Article
- Evaluating long-term care insurance policies in China: an integrated analysis of policy instruments and PMC index model.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The high-quality development of the traditional Chinese medicine (TCM) industry is dependent on supportive policies and requires higher levels of coordination and integration. National and local government policies must coordinate the integrated development of the TCM industry under modern governance principles. However, the policy structure and its impact on the development of the TCM industry have not been thoroughly explored from the perspectives of policy design and empirical evidence. Methods: A TCMIDPs evaluation system was established using the PMC-Index model to quantitatively analyze TCMIDPs in China and Shaanxi Province. Additionally, principal component analysis (PCA) was used to comprehensively evaluate 51 enterprises in Shaanxi Province. Results: The policy analysis shows that the average PMC index of the 31 TCM industry development policies is 5.080, indicating that the areas and functions covered by these policies need improvement. The comprehensive evaluation reveals that pharmaceutical enterprises in Shaanxi Province still exhibit unbalanced development. Conclusion: Future TCM industry policies should focus on long-term industrial development, incorporating comprehensive perspectives. Emphasis should be placed on strengthening enterprise R&D, accelerating pharmaceutical innovation, and promoting the holistic development of pharmaceutical enterprises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.